FY2025 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreased by Zacks Research

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Zacks Research cut their FY2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a report issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.93 for the year, down from their previous forecast of $0.94. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

A number of other equities analysts have also weighed in on ACAD. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 10th. Morgan Stanley decreased their price objective on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 13th. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 30th. Finally, Royal Bank of Canada reduced their price target on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.82.

ACADIA Pharmaceuticals Trading Down 1.5 %

Shares of ACAD stock opened at $16.74 on Tuesday. ACADIA Pharmaceuticals has a 12 month low of $16.60 and a 12 month high of $33.99. The stock has a market cap of $2.76 billion, a P/E ratio of -44.05 and a beta of 0.37. The company has a 50 day simple moving average of $20.64 and a two-hundred day simple moving average of $23.72.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). The firm had revenue of $231.04 million for the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. ACADIA Pharmaceuticals’s quarterly revenue was up 69.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.26) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ACAD. Quest Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth about $39,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $100,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ACADIA Pharmaceuticals by 97.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,202 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 2,070 shares in the last quarter. Legato Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $206,000. Finally, Old Well Partners LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $257,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling

In other news, insider James Kihara sold 1,790 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $17.87, for a total transaction of $31,987.30. Following the completion of the transaction, the insider now directly owns 13,100 shares in the company, valued at $234,097. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other ACADIA Pharmaceuticals news, insider James Kihara sold 1,790 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the sale, the insider now directly owns 13,100 shares of the company’s stock, valued at approximately $234,097. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Stephen Davis sold 5,577 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, February 26th. The stock was sold at an average price of $24.67, for a total transaction of $137,584.59. Following the sale, the chief executive officer now directly owns 101,890 shares of the company’s stock, valued at $2,513,626.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,383 shares of company stock valued at $1,291,362. 27.50% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.